CTOs on the Move

Istari Oncology

www.istarioncology.com

 
Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Istari Oncology raised $43.4M on 04/22/2021

Similar Companies

BioExx Specialty Proteins

BioExx Specialty Proteins Ltd. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

General Automation Lab Technologies

General Automation Lab Technologies (GALT), a San Francisco-based life science company, is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes.

Church Street Health Management

"Our company`s promise is in our name - CSHM - Committed to Smiles and a Healthy Mouth. Our mission is to ensure access to quality, professional dental care for low-income, underserved families and those seeking comprehensive care. Our dental centers are creating access to dental health services for these families – and especially their children – who are often least able to afford care."

Ontario Genomics Institute

Ontario Genomics Institute is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Absci

Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.